# Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim

> **NCT03057418** · PHASE1 · COMPLETED · sponsor: **Biointegrator LLC** · enrollment: 7 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Lymphoma, Follicular

## Interventions

- **DRUG:** Aurixim

## Key facts

- **NCT ID:** NCT03057418
- **Lead sponsor:** Biointegrator LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057418, "Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03057418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*